AFFILIATIONS

Department of Pediatrics (Division of Pediatric Hematology and Oncology)

Experimental Therapeutics Cancer Center Program

High Risk Leukemia and Lymphoma Program, Primary Children’s Hospital (Medical Director)

Member, Hematologic Malignancies DOT

Data and Safety Monitoring Committee (Chair)

Medical Director, Research Compliance Office

bronner group banner

Publications

adobe Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Raetz E, Perkins S, Bhojwani D, Smock K, Philip M, Carroll W and Min, D.  
Pediatr Blood Cancer 2006;47:130-40. PMID:  16358311.
adobe Biological pathways associated with relapse in childhood acute lymphoblastic leukemia: A Children’s Oncology Group Study. 
Bhojwani D, Kang H, Moskowitz N, Min D, Belitskaya-Levy I , Lee H, Potter J, Davidson G, Willman C,. Borowitz M, Hunger S, Raetz E and Carroll W. 
Blood 2006;108:711-7.  PMID:  16822902.
adobe Risk and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). 
Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, Carroll AJ, Heerema NA, Rubnitz JE, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Gaynon PS, Camitta BM. 
Blood 2007; 109:926-35. PMID:  17003380.
adobe

Molecular pathogenesis of T-cell leukaemia and lymphoma.
Aifantis I, Raetz E, Buonamici S.
Nat Rev Immunol 2008;8:380-90. PMID:  18421304.

Chemoimmunotherapy re-induction with epratuzumab in children with ALL in marrow relapse: A Children’s Oncology Group (COG) pilot study (ADVL04P2). 
Raetz E, Cairo, M, Borowitz M, Blaney S, Krailo M, Leil T, Reid J, Goldenberg D, Wegener W, Carroll W and Adamson P.
J Clin Oncol 2008; 26:3756-62.  PMID:  18669463.
adobe Re-induction platform for children with first marrow relapse of acute lymphoblastic leukemia:  A Children s Oncology Group (COG) study.
Raetz E, Michael J. Borowitz, Meenakshi Devidas, Stephen B. Linda, Stephen P. Hunger, Naomi J. Winick, Bruce M. Camitta, Paul S. Gaynon and William L. Carroll. 
J Clin Oncol 2008; 26:3971-8.  PMID:  18711187.
adobe Improving outcomes for high-risk ALL:  Translating new discoveries into clinical care. 
Hunger S, Raetz E, Loh M, Mullighan C. 
Pediatr Blood Cancer 2011;56:984-993.  PMID:  21370430.
adobe Endogenous knock-down of survivin improves chemotherapeutic response in ALL models.
Morrison D, Hogan L, Condos, G, Bhatla T, Germino N, Moskowitz N, Lee L, Bhojwani D, Horton, T, Belitskaya-Levy I, Greenberger L, Horak I, Grupp S, Teachey D, Raetz E, Carroll W.   
Leukemia 2012;26:271-279.
adobe Clinical and Laboratory Biology of Childhood Acute Lymphoblastic Leukemia. 
Carroll W and Raetz E
J Pediatr 2011;160:10-18.  PMID:  21920540.
adobe Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. 
Hogan L, Meyer J, Yang J, Wang J, Wong N, Yang W, Condos G, Hunger S, Raetz E, Safffery R, Relling M, Bhojwani D, Morrison D, Carroll W. 
Blood 2011;118:5218-26.  PMID:  21921043.
adobe Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.
Bhatla T, Wang J, Morrison DJ, Raetz E, Burke M, Brown P and Carroll W.
Blood 2012;  119:5201-10. PMID:  22496163.
adobe Children’s Oncology Group’s 2013 Blueprint for Research: Acute Lymphoblastic Leukemia.
Hunger S, Loh M, Whitlock J, Winick N, Carroll W, Devidas M and Raetz E
Pediatr Blood Cancer 2013; 60(6):957-63.  PMID:  23255467.
adobe Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.
Meyer JA, Wang J, Hogan LE, Yang JJ, Dandekar S, Patel JP, Tang Z, Zumbo P, Li S, Zavadil J, Levine RL, Cardozo T, Hunger SP, Raetz EA, Evans WE, Morrison DJ, Mason CE, Carroll WL.  
Nat Genet 2013;45:290-4. PMID:  23255467
A Phase I Study of EZN-3042, a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist, Administered in Combination with Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia (ALL):  A Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
Raetz E, Morrison D, Romanos-Sirakis E, Gaynon P, Sposto R, Bhojwani D, Bostrom B, Brown P, Eckroth E, Cassar J, Malvar J, Buchbinder A, Carroll W.
J Pediatr Hematol Oncol. 2013 Oct 31. [Epub ahead of print]
adobe Intrachromosomal Amplification of Chromosome 21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia on Contemporary Standard Risk Children’s Oncology Group Studies, A Report from the Children’s Oncology Group.
Heerema N, Carroll A, Devidas M, Loh M, Borowitz M, Gastier-Foster J P, Larsen E, Mattano L, Maloney K, Willman C, Wood B, Winick N, Carroll W, Hunger S, Raetz E
J Clin Oncol. 2013;31(27):3397-402.  PMID:  23940221.
adobe

Refining prognosis in BCR-ABL1-positive ALL. 
Raetz E and Carroll W. 
Blood. 2014 Mar 13;123(11):1626-7.

The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions.
Bhatla T, Jones CL, Meyer JA, Vitanza NA, Raetz EA, Carroll WL.
J Pediatr Hematol Oncol. 2014; 36(6):413-8.  PMID:  24942923.
adobe Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance.
Vitanza NA, Zaky W, Blum R, Meyer JA, Wang J, Bhatla T, Morrison DJ, Raetz EA, Carroll WL.  
Pediatr Blood Cancer. 2014;61(10):1779-85. 
adobe Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia.
Dandekar S, Romanos-Sirakis E, Pais F, Bhatla T, Jones C, Bourgeois W, Hunger SP, Raetz EA, Hermiston ML, Dasgupta R, Morrison DJ, Carroll WL.
Br J Haematol. 2014 Jul 4. doi: 10.1111/bjh.13011. [Epub ahead of print]